We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$279M
Cap. Flow %
-2.91%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 89.03%
2 Financials 0.34%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$67.9B
$541M 5.64%
23,129,200
+649,500
+3% +$14.1M
AMGN icon
2
Amgen
AMGN
$213B
$462M 4.82%
3,033,500
+157,500
+5% +$24.5M
ABBV icon
3
AbbVie
ABBV
$469B
$407M 4.25%
6,573,100
-822,600
-11% -$50.1M
BMY icon
4
Bristol-Myers Squibb
BMY
$130B
$372M 3.88%
5,055,600
-2,569,300
-34% -$182M
BIIB icon
5
Biogen
BIIB
$32B
$363M 3.79%
1,500,400
-25,900
-2% -$6.83M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$348M 3.63%
2,981,411
+1,110,811
+59% +$158M
HCA icon
7
HCA Healthcare
HCA
$90.9B
$316M 3.29%
4,098,300
-1,638,800
-29% -$129M
AGN
8
DELISTED
Allergan plc
AGN
$311M 3.24%
1,344,615
-228,100
-15% -$52.6M
GILD icon
9
Gilead Sciences
GILD
$166B
$256M 2.67%
3,072,900
+53,700
+2% +$4.77M
CELG
10
DELISTED
Celgene Corp
CELG
$237M 2.47%
2,404,677
-1,369,400
-36% -$142M
WCG
11
DELISTED
Wellcare Health Plans, Inc.
WCG
$206M 2.15%
1,918,500
+15,200
+0.8% +$1.49M
TMO icon
12
Thermo Fisher Scientific
TMO
$215B
$203M 2.12%
1,377,200
-57,800
-4% -$8.53M
ISRG icon
13
Intuitive Surgical
ISRG
$128B
$197M 2.06%
2,680,200
+189,000
+8% +$13.3M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$125B
$188M 1.97%
2,189,300
+319,900
+17% +$27.6M
INCY icon
15
Incyte
INCY
$25.7B
$186M 1.94%
2,324,678
-430,400
-16% -$33.4M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$73.1B
$178M 1.86%
509,900
-23,100
-4% -$8.9M
UNH icon
17
UnitedHealth
UNH
$387B
$171M 1.78%
1,208,200
+396,200
+49% +$52.8M
IPXL
18
DELISTED
Impax Laboratories, Inc.
IPXL
$170M 1.77%
5,886,700
-889,400
-13% -$29M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$160M 1.67%
1,120,000
– –
A icon
20
Agilent Technologies
A
$39.9B
$158M 1.65%
3,565,200
+70,200
+2% +$3.03M
PFE icon
21
Pfizer
PFE
$144B
$149M 1.56%
4,472,860
+128,272
+3% +$4.09M
TEVA icon
22
Teva Pharmaceuticals
TEVA
$39.9B
$139M 1.45%
2,759,800
+63,800
+2% +$3.4M
RLYP
23
DELISTED
RELYPSA INC COM
RLYP
$137M 1.43%
7,400,000
– –
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$616M
$130M 1.36%
11,879,106
-1,912,072
-14% -$18.7M
ESRX
25
DELISTED
Express Scripts Holding Company
ESRX
$129M 1.34%
1,698,600
-722,400
-30% -$53.1M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q2 2016 filing shows 16 new, 39 increased, 32 reduced and 21 closed positions. Its largest new stake was Molina Healthcare: 1,838,000 shares worth $91.7M. The largest sale was Bristol-Myers Squibb, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.